Πέμπτη 19 Οκτωβρίου 2017

CTD^2: Bridging Genomics to Therapeutics

The Cancer Target Discovery and Development (CTD^2) initiative was established by the National Cancer Institute (NCI) to bridge the gap between cancer genomics and precision oncology and has developed many approaches for identifying therapeutic targets, perturbagens, and biomarkers. CTD^2 is currently exploring cancer heterogeneities and developing strategies to overcome treatment resistance.



from Cancer via ola Kala on Inoreader http://ift.tt/2xRLF2u
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου